🚨 NEW COMMENT ⚕️💡
Desachy et al. reflect on the Precision Medicine Initiative after a decade and share their perspective as pharmaceutical statisticians while proposing strategic shifts to realize its full potential.
📢 Communication Medicine will be at the 37th Pezcoller Symposium ‘CANCER EVOLUTIONARY TRAJECTORIES’ next week June 22-23rd 🎉
📩 Our editor Katharine Barnes will be attending and would love to connect with researchers! Get in touch to schedule a meeting.
#Pezcoller26 #academicsky⚕️🩺
🚨 NEW COMMENT ⚕️💡
Calvert et al. summarise evidence on the value of patient-reported outcomes throughout the drug development pipeline and provide a summary of guidance documents to support optimal assessment in drug development.
🚨 NEW REVIEW⚕️ 🩺
Zhu et al. discusses specific epigenetic regulatory mechanism of hepatocytes during the occurrence of MASLD, as well as possible therapeutic targets and therapies for these modifications.
http://dlvr.it/TSwqbc
#Epigenetics #MASLD
@commsmed.nature.com
rdcu.be/fmkIz
🚨 NEW COLLECTION! 💡
Submit your research on “The expanding therapeutic landscape of GLP 1 receptor agonists”
This Collection calls for papers that investigate the expanding clinical and biological roles of GLP‑1 RAs.
http://dlvr.it/TSMMmV
#GLP1Agonists
🚨 NEW COMMENT ⚕️💡
Xiong et al. discuss the Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Initiative, funded with $88 million over five years, which aims to advance health research across Africa.
🚨 NEW REVIEW⚕️ 🩺
Tao et al. summarize evidence linking HIV-1 Env sequence characteristics to reduced bnAb susceptibility, including in vivo selection data in animal models and human studies, and in vitro selection and susceptibility data.
A study in Communications Medicine explores whether a special, fat-based diet could be a safe and effective treatment for adults with anorexia nervosa. Participants showed significant improvements in eating disorder symptoms. go.nature.com/4dT0WCA #medsky 🧪
🚨 NEW REVIEW⚕️ 🩺
Sridharan et al . examine the potential contributing role of microplastics and nanoplastics in prostate, bladder, and renal cell carcinoma as well as their potential in therapeutics as advanced drug delivery platforms.